Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics
Viruses · 2024
DOI: 10.3390/v16050669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Yufei Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, HLA-A11 Antigen, HLA-A2 Antigen, Nasopharyngeal Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China Grant, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Epstein-Barr Virus (EBV) is closely linked to nasopharyngeal carcinoma (NPC), notably prevalent in southern China. Although type II latency of EBV plays a crucial role in the development of NPC, some lytic genes and intermittent reactivation are also critical for viral propagation and tumor progression. Since T cell-mediated immunity is effective in targeted killing of EBV-positive cells, it is important to identify EBV-derived peptides presented by highly prevalent human leukocyte antigen class I (HLA-I) molecules throughout the EBV life cycle. Here, we constructed an EBV-positive NPC cell model to evaluate the presentation of EBV lytic phase peptides on streptavidin-tagged specific HLA-I molecules. Utilizing a mass spectrometry (LC-MS/MS)-based immunopeptidomic approach, we characterized eleven novel EBV peptides as well as two previously identified peptides. Furthermore, we determined these peptides were immunogenic and could stimulate PBMCs from EBV VCA/NA-IgA positive donors in an NPC endemic southern Chinese population. Overall, this work demonstrates that highly prevalent HLA-I-specific EBV peptides can be captured and functionally presented to elicit immune responses in an in vitro model, which provides insight into the epitopes presented during EBV lytic cycle and reactivation. It expands the range of viral targets for potential NPC early diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
- Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangdong-Hong Kong Joint Laboratory for Stem Cell and Regenerative Medicine, Center for Cell Lineage and Development, Guangzhou Institutes of…
- Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou Medical University, Guangzhou 511436, China.
ORCID-Profile: Ruona Shi, Zhenhuan Feng, Xiaofei Zhang, Miao Xu
Förderung
- National Key Research and Development Program of China Grant
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province
- Major Project of Guangzhou National Laboratory
- Guangdong Pearl River Talents Program
Zitieren
APA
Wang, Y., Zhang, W., Shi, R., Luo, Y., Feng, Z., Chen, Y., Zhang, Q., Zhou, Y., Liang, J., Ye, X., Feng, Q., Zhang, X., & Xu, M. (2024). Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics. Viruses. https://doi.org/10.3390/v16050669
Vancouver
Wang Y, Zhang W, Shi R, Luo Y, Feng Z, Chen Y, et al. Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics. Viruses. 2024. doi:10.3390/v16050669
BibTeX
@article{Wang2024,
author = {Wang, Yufei and Zhang, Wanlin and Shi, Ruona and Luo, Yanran and Feng, Zhenhuan and Chen, Yanhong and Zhang, Qiuting and Zhou, Yan and Liang, Jingtong and Ye, Xiaoping and Feng, Qisheng and Zhang, Xiaofei and Xu, Miao},
title = {Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16050669}
}
EUVIMED